How to Find Heart Disease: Symptoms, Tests, and Screenings

Heart disease often develops silently over years, sometimes decades, before it announces itself with chest pain or something worse. Catching it early depends on recognizing symptoms that are easy to dismiss, choosing the right tests for your situation, and understanding that no single scan or blood draw tells the whole story. The tools available today range from a simple blood test that can flag heart muscle damage within an hour to imaging that maps calcium deposits in your arteries before you ever feel a thing. Knowing which tools exist and when they matter can make the difference between prevention and emergency.

Symptoms Are Less Obvious Than You Think

The classic image of a heart attack involves clutching the chest in sudden pain. That does happen, but it is far from the only way heart disease shows up. Fatigue, shortness of breath during routine activity, lightheadedness, jaw or back pain, and nausea all qualify as cardiac symptoms, and they are especially common in women. In one study of women presenting with a heart attack, roughly 85% arrived with these “atypical” symptoms like dizziness, sweating, palpitation, and fatigue rather than classic chest pain, compared with about 70% of men. Women more often described squeezing or tightness, while men reported burning or pricking sensations.¹

Then there is the possibility of no symptoms at all. Silent myocardial ischemia, where the heart muscle does not get enough blood but produces no noticeable discomfort, remains one of the trickiest problems in cardiology. Because there is nothing to prompt a doctor visit, the condition often goes undetected until it triggers a serious event.² People with diabetes are particularly prone to silent ischemia because nerve damage can blunt the pain signals the heart would normally send.

The takeaway is that waiting for a dramatic warning sign is not a reliable strategy. Persistent unexplained fatigue, worsening exercise tolerance, or feeling winded climbing stairs you used to handle easily all deserve a conversation with your doctor, even if chest pain is nowhere in the picture.

Blood Tests That Spot Heart Trouble

Two families of blood biomarkers have transformed how doctors evaluate the heart. The first, high-sensitivity cardiac troponin, detects tiny amounts of a protein released when heart muscle cells are injured. Current guidelines from the American Heart Association and American College of Cardiology recognize high-sensitivity troponin as the preferred biomarker for evaluating acute chest pain.³ Older troponin assays could miss small heart attacks or require hours of waiting for levels to rise. The high-sensitivity versions can accurately detect heart muscle injury from a blood draw taken when you first arrive at the emergency department, cutting the time needed to confirm or rule out a heart attack substantially.⁴

The second group of biomarkers involves natriuretic peptides, specifically BNP and NT-proBNP. The heart releases these when its walls are stretched or under pressure, making them useful markers for heart failure. If you show up with unexplained shortness of breath or fatigue, a natriuretic peptide test can help your doctor figure out whether the heart is struggling to pump effectively.⁵ These peptides have a very high ability to rule heart failure out: when levels come back low, the probability that heart failure is causing your symptoms drops to somewhere around 3 to 6%.⁵ Among the two peptides, NT-proBNP appears to be somewhat better at catching mild or early-stage heart failure.⁶

Neither troponin nor natriuretic peptides by themselves give a complete diagnosis. A troponin spike tells you heart cells have been damaged but not why. BNP can be elevated in kidney disease, obesity, or lung conditions. These tests are most powerful when combined with imaging and clinical judgment, which is why doctors treat them as pieces of a puzzle rather than standalone verdicts.

The Resting ECG and Its Limits

An electrocardiogram, or ECG, is usually the first test ordered when heart disease is suspected. It records the heart’s electrical activity through electrodes placed on the skin and takes under a minute. In an acute setting, an ECG can immediately reveal a heart attack in progress or a dangerous rhythm disturbance. For chronic coronary artery disease, though, a resting ECG is much less reliable. In one study of patients with confirmed stable coronary disease, almost half had a completely normal resting ECG. The sensitivity for picking up the typical ischemic pattern was only about 23%, meaning the test missed most cases, though its specificity was higher at around 87%.⁷ Even among patients whose ECGs looked perfectly normal, over half turned out to have significant blockages when examined more closely.

A normal ECG does not mean a healthy heart, and an abnormal ECG does not always mean a sick one. For emergency situations or arrhythmia detection, the ECG remains indispensable. For catching chronic coronary disease in someone without active symptoms, it is a starting point at best. The U.S. Preventive Services Task Force actually recommends against screening asymptomatic low-risk adults with resting or exercise ECGs, concluding that the potential harms, including false positives that lead to unnecessary procedures, equal or exceed the potential benefits in that group.⁸

Coronary Artery Calcium Scoring

A coronary artery calcium (CAC) scan uses a quick, low-dose CT scan to measure calcium deposits in the walls of the heart’s arteries. Calcium builds up in arterial plaque over time, so the amount present serves as a rough gauge of how much atherosclerosis has accumulated. The scan produces a score: zero means no detectable calcium, and higher numbers indicate more extensive plaque. A score of zero is one of the strongest negative predictors in cardiology, meaning it effectively “de-risks” a patient for near-term events.⁹

How much does a high score actually matter? In a study of more than 10,000 adults without known heart disease, age-adjusted rates of serious events like heart attack or cardiac death climbed steeply with rising calcium scores. For men, the rate went from 0.4 per 1,000 person-years with no detectable calcium to 8.7 per 1,000 person-years in the highest calcium group.¹⁰ Another large study found that participants with scores above 300 had nearly four times the risk of a cardiac event compared to those with a score of zero, and this association held even after accounting for traditional risk factors.¹¹

Despite these results, the USPSTF has said the evidence is not yet sufficient to recommend for or against using calcium scoring as part of routine cardiovascular risk assessment in asymptomatic adults.¹² The ACC/AHA guidelines, however, have incorporated calcium scoring as a tool for people in the borderline or intermediate risk range, where the result can help decide whether to start or intensify preventive treatment like statins. If your doctor is on the fence about your risk level, a calcium score of zero can provide genuine reassurance, while a high score can motivate more aggressive prevention.

CT Angiography for Visualizing Blockages

Where a calcium score tells you plaque exists, a coronary CT angiography (CCTA) actually shows you the arteries themselves. After injecting contrast dye into a vein, the scanner produces detailed images of the coronary vessels and can identify narrowings. In the prospective ACCURACY trial, CCTA achieved a sensitivity of about 95% and a negative predictive value of 99% for detecting blockages of 50% or greater, meaning it rarely missed significant disease.¹³ A second multicenter study found somewhat lower but still strong sensitivity around 85%, with a specificity of 90%, and confirmed that CT angiography performed comparably to traditional invasive catheterization in identifying patients who ultimately needed a procedure.¹⁴

The real strength of CCTA is its ability to spare people from invasive catheterization when their arteries turn out to be clear. If the scan shows no significant blockages, you can generally avoid having a catheter threaded into your heart. Where specificity dips, though, false positives can occur, occasionally flagging a narrowing that is not as severe as it looks on CT. That is why a positive CCTA result sometimes leads to further testing to confirm the finding before any intervention happens.

Stress Testing and When It Helps

Stress tests push the heart to work harder, either through exercise on a treadmill or with a medication that simulates the effect, while monitoring for signs of ischemia. The classic exercise stress test with ECG monitoring is the simplest version. A large meta-analysis pooling over a hundred studies found that exercise ECG stress testing had pooled sensitivity and specificity of roughly 64% and 62% for detecting obstructive coronary disease, which is the lowest among all the stress modalities.¹⁵ That means the exercise ECG misses about a third of people with real blockages and incorrectly flags about a third of people who are fine.

Adding imaging sharpens the picture. Stress echocardiography, which watches the heart’s wall motion under stress using ultrasound, improves accuracy. Nuclear stress tests, where a radioactive tracer highlights blood flow through the heart, do too. The best performers in the meta-analysis were cardiac MRI-based stress tests: drug-induced stress MRI reached a sensitivity around 85% and accuracy near 87%, while exercise MRI had the highest specificity at about 92%.¹⁵ Stress testing remains most useful for people with intermediate-probability symptoms, where the pre-test likelihood of disease is neither very low nor very high. If your risk is very low, a stress test is more likely to produce a misleading false positive than to find real disease.

Echocardiography and Cardiac MRI for Heart Muscle Assessment

Not all heart disease involves blocked arteries. Heart failure, cardiomyopathies, and valve disorders affect the muscle and structures of the heart itself, and the tools for diagnosing these differ from those that look at the coronary vessels.

Echocardiography, essentially an ultrasound of the heart, is considered the standard for assessing how well the heart muscle pumps. It can measure ejection fraction, detect valve leaks, spot thickened or thinned walls, and evaluate structural remodeling that occurs as heart failure progresses.¹⁶ It is portable, widely available, uses no radiation, and can be repeated as often as needed to track changes over time. When a patient shows up with new shortness of breath and elevated BNP, an echocardiogram is typically the next step.

Cardiac MRI goes deeper. Its ability to characterize tissue, not just structure, sets it apart. A technique called late gadolinium enhancement can distinguish ischemic heart disease from non-ischemic cardiomyopathies by revealing patterns of scarring within the heart muscle. Ischemic scars follow the territory of a blocked artery, while non-ischemic patterns are more diffuse or affect the mid-wall.¹⁷ Newer MRI mapping techniques can detect subtle disease processes in conditions like hypertrophic or dilated cardiomyopathy even when conventional imaging looks unremarkable.¹⁸ Cardiac MRI is not something everyone needs, but when the diagnosis remains uncertain after echocardiography or when a specific cardiomyopathy is suspected, it is often the test that settles the question.

Smartwatches and Arrhythmia Detection

Consumer wearables have entered cardiac diagnostics in a way that would have seemed implausible a decade ago. A systematic review and meta-analysis covering over 17,000 patients found that smartwatches detected atrial fibrillation with an overall sensitivity of 95% and specificity of 97%.¹⁹ Performance varied somewhat by brand, with Apple Watch achieving about 94% sensitivity and 97% specificity, and Samsung devices reaching 97% sensitivity and 96% specificity.¹⁹

A separate study compared wearable smartwatch algorithms against implanted continuous monitors and found that smartwatch-based detection outperformed commonly used strategies like intermittent Holter or patch monitors for picking up atrial fibrillation episodes.²⁰ The correlation between smartwatch-measured and clinically measured atrial fibrillation burden exceeded 0.97, which is remarkably tight agreement.

The catch is that these numbers come from curated study populations. In everyday life, wrist movement, poor contact, and low heart rate variability can cause false alerts. A smartwatch notification is not a diagnosis; it is a prompt to get a confirmatory ECG. Still, for people with intermittent palpitations that never seem to appear during a scheduled doctor visit, a wearable that catches the rhythm in real time can be genuinely useful.

Risk Prediction Scores and Their Real-World Accuracy

Before ordering any test, your doctor may calculate a risk score, plugging in your age, cholesterol, blood pressure, smoking status, and other factors to estimate your likelihood of a cardiovascular event over the next ten years. The Framingham Risk Score is one of the oldest and most widely used, but it is not the only option. A meta-analysis of validation studies found that Framingham had pooled sensitivity of about 79% and specificity of about 66%, while the ACC/AHA model came in at around 74% sensitivity and 79% specificity.²¹

These scores work reasonably well at the population level but can be unreliable for individuals. An earlier systematic review found that Framingham-based tools could undershoot actual risk by more than half in high-risk groups or overshoot it nearly threefold in lower-risk populations.²² The models were developed largely in white American and European populations, so they tend to miscalibrate when applied to different ethnic groups or geographic settings. If you are told you are “low risk” by a score, that is not a guarantee. It means the average person with your numbers tends to do well. Your individual biology, family history, and factors the score does not capture can shift your real risk in either direction.

When Arteries Look Clear but the Heart Still Hurts

An increasingly recognized challenge involves people, more often women, who have classic angina symptoms and evidence of ischemia on testing but whose coronary arteries look perfectly open during angiography. This condition goes by INOCA (ischemia with no obstructive coronary arteries) or ANOCA (angina with no obstructive coronary arteries). Standard angiography simply cannot see the problem because it lives in the tiny microvascular branches rather than the large epicardial vessels.²³

Diagnosing INOCA typically requires specialized invasive tests during catheterization. Doctors can measure coronary flow reserve and microvascular resistance using pressure and temperature wires inside the artery, and they can provoke spasm with acetylcholine to test for vasospastic angina.²⁴ The CorMicA trial showed that correctly identifying the specific subtype, whether microvascular angina, vasospastic angina, or non-cardiac chest pain, leads to better outcomes because treatment can be tailored rather than generic.²³ If you have been told your arteries are “fine” but your symptoms persist, INOCA testing is worth discussing with a cardiologist.

Genetic Screening for Familial High Cholesterol

Most heart disease screening focuses on what has already happened inside your body, whether plaque, muscle damage, or rhythm problems. Genetic screening is an exception: it can identify people at high risk before any damage is visible. Familial hypercholesterolemia (FH) is the prime example. It is a genetic condition that causes dangerously elevated LDL cholesterol from birth, dramatically accelerating atherosclerosis. Most people with FH do not know they have it.

The most cost-effective way to find FH cases is cascade screening, which means genetically testing close relatives of someone already diagnosed.²⁵ Because FH follows a clear inheritance pattern, about half of first-degree relatives will carry the same mutation. Research indicates that cascade screening delivers real health benefits and is cost-effective without causing psychological or social harm, yet national programs remain inconsistent.²⁵ The European Commission recently recognized pediatric FH screening as a best practice in non-communicable disease prevention, reflecting the view that lowering LDL cholesterol across a lifetime substantially reduces coronary artery disease risk.²⁶ If you have a parent or sibling diagnosed with very high cholesterol at a young age, or a family history of early heart attacks, asking about FH testing is one of the highest-yield steps you can take.

Disparities in Who Gets Diagnosed

Access to the diagnostic tools described in this article is uneven. Cardiovascular disease and its risk factors are more common among marginalized racial, ethnic, and Indigenous populations, but these groups also face greater barriers to accessing cardiovascular care, widening the health equity gap.²⁷ Advanced imaging like cardiac MRI and calcium scoring tends to concentrate in well-resourced urban medical centers. Rural patients may have access to basic ECGs and blood tests but face long travel distances for stress imaging or catheterization. Insurance coverage plays a role too: a coronary calcium scan is often not covered for routine screening, putting it out of reach for many people despite its prognostic value.

The gender dimension matters independently. Women’s atypical symptom patterns, discussed earlier, combine with less aggressive clinical workups to create diagnostic delays. Risk scores developed in predominantly male populations can underestimate women’s risk. And INOCA, which disproportionately affects women, requires specialized testing that many catheterization labs still do not routinely offer. Awareness of these gaps is the first step toward closing them, both for patients who can advocate for themselves and for health systems designing screening programs.

Invasive Catheterization and Functional Assessment

When non-invasive testing raises serious concern about significant coronary disease, invasive coronary angiography, where a catheter is threaded through an artery to directly inject dye into the coronary vessels, remains the definitive method for visualizing blockages. It also doubles as a gateway to treatment: if a severe narrowing is found, a stent can sometimes be placed during the same procedure.

A key limitation of angiography is that a narrowing that looks moderate on imaging may or may not actually restrict blood flow enough to cause symptoms or damage. Fractional flow reserve (FFR) measurement addresses this by using a pressure-sensing wire to determine whether a specific blockage is actually starving the heart of blood. Recent research has also explored computational approaches that estimate FFR from the angiography images themselves, without an extra wire. In a multicenter pilot study, the best computational algorithms achieved diagnostic accuracy around 86 to 87% compared to wire-based FFR.²⁸ If these computational methods continue to improve, they could reduce the need for additional invasive measurements during catheterization, saving time and minimizing risk.

Invasive angiography carries small but real risks, including bleeding at the catheter insertion site, allergic reactions to contrast dye, and in rare cases, stroke or heart attack triggered by the procedure itself. For this reason, it is reserved for situations where non-invasive testing has already pointed toward likely significant disease or where the clinical picture is urgent enough to warrant going straight to the catheterization lab.

1
PubMed Central. Atypical Manifestations of Women Presenting with Myocardial Infarction at Tertiary Health Care Center: An Analytical Study
2
PubMed Central. Silent Myocardial Ischemia: From Pathophysiology to Diagnosis and Treatment
3
PubMed. High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain
4
PubMed. Clinical Use of High-Sensitivity Cardiac Troponin in Patients With Suspected Myocardial Infarction
5
Journal of Cardiac Failure. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure
6
Clinical Chemistry. Comparison of Brain Natriuretic Peptide (BNP) and Amino-Terminal ProBNP for Early Diagnosis of Heart Failure
7
PubMed. The diagnostic value of resting electrocardiography in stable coronary artery disease
8
Journal of the American Medical Association. Cardiovascular Disease Risk: Screening With Electrocardiography
9
PubMed Central. Coronary Artery Calcium Scoring in Asymptomatic Patients
10
American Journal of Epidemiology. Coronary Artery Calcium Score and Coronary Heart Disease Events in a Large Cohort of Asymptomatic Men and Women
11
JAMA. Coronary Artery Calcium Score Combined With Framingham Score for Risk Prediction in Asymptomatic Individuals
12
JAMA. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement
13
PubMed. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY trial
14
PubMed. Diagnostic performance of coronary angiography by 64-row CT
15
PubMed Central. Diagnostic Accuracy of Exercise Stress Testing, Stress Echocardiography, Myocardial Scintigraphy, and Cardiac Magnetic Resonance for Obstructive Coronary Artery Disease: Systematic Reviews and Meta-Analyses of 104 Studies Published from 1990 to 2025
16
PubMed Central. Role of echocardiography in diagnosis and risk stratification in heart failure with left ventricular systolic dysfunction
17
PubMed Central. Myocardial tissue characterization by magnetic resonance imaging: novel applications of T1 and T2 mapping
18
PubMed. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy
19
PubMed Central. Accuracy of Smartwatches in the Detection of Atrial Fibrillation: A Systematic Review and Diagnostic Meta-Analysis
20
PubMed Central. Wearable smartwatches for atrial fibrillation detection and burden estimation after ablation: comparison with continuous monitoring
21
PubMed Central. Diagnostic Accuracy of Cardiovascular Disease Prediction Models: A Systematic Review and Meta-Analysis of Validation Studies
22
PubMed Central. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review
23
PubMed Central. How to Diagnose and Manage Angina Without Obstructive Coronary Artery Disease: Lessons from the British Heart Foundation CorMicA Trial
24
PubMed Central. INOCA/ANOCA: Mechanisms and novel treatments
25
PubMed. Cascade genetic screening for familial hypercholesterolemia
26
PubMed Central. Genetic Testing in Familial Hypercholesterolemia: Is It for Everyone?
27
PubMed Central. Reducing inequalities in cardiovascular disease: focus on marginalized populations considering ethnicity and race
28
JACC: Cardiovascular Interventions. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study